
€1M Grant from Bpifrance’s Innovation Prize
February 20, 2019
March 22, 2019
[EVENTS] Company ; METAglut1™
We had the honor of presenting at the 47th Annual Meeting of the Société Européenne de Neurologie Pédiatrique (SENP), a key event dedicated to advancing the field of pediatric neurology in Europe.
This gathering brought together leading experts and practitioners in pediatric neurology to discuss the latest research and advancements in the field.
METAglut1™ is our innovative rapid IVD blood test, designed to aid the early diagnosis of GLUT1DS.
Glut1 Deficiency Syndrom (Glut1DS), also known as De Vivo Disease, is a rare neuro metabolic disorder that can significantly impact the lives of affected children.
We believe that our diagnostic tool represents a significant advancement in identifying the condition, which can have profound implications for affected individuals and their families.
We were particularly proud to have the intermediate results of our validation study for METAglut1™ presented by Dr. Odile Boespflug-Tanguy, a neuropediatrician from the AP-HP Paris Region Hospitals (Assistance-Publique – Hôîtaux de Paris).
POSTER PRESENTATION:
“Evaluating the performance of METAglut1 in patients whose clinical presentation is compatible with the glucose transporter 1 deficiency syndrome (Glut1-DS)“
The Société Européenne de Neurologie Pédiatrique (SENP+) is an international society made up of specialists in pediatric neurology, practicing in the south-western part of the European Community: France, Italy, Portugal, Belgium, Switzerland, Luxembourg and Spain.
Every year, the SENP+ organizes meetings reserved for members of the association and a few invited guests – mostly future candidate-members. At these meetings, participants discuss a series of predefined topics in collaboration with experts (members and non-members of the Society).
Since its creation, the SENP+ has played an active role in the development of pediatric neurology. All SENP+ members have been pioneers in the creation of pediatric neurology societies in their countries. The SENP+ is committed to providing warm, human-scale meetings that encourage exchanges between professionals and the development of caring collaborations for the benefit of young neuropediatricians in training.
Sharing our validation study results at the 47th Annual Meeting of the Société Européenne de Neurologie Pédiatrique (SENP), has invigorated our commitment to advancing research and innovation in pediatric health. We are dedicated to collaborating with experts and stakeholders to improve patient outcomes and have the test as fast as possible covered and available.